Hemostatic Composition Using Zeolite and Trypsin
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current hemostatic materials, including inorganic zeolites and biological agents like thrombin, face challenges in achieving rapid and effective hemostasis, especially in emergency situations and for patients with hemophilia, due to long coagulation times and high costs, as well as inactivation of enzymes on zeolite surfaces.
Innovation Solution
A bio-inorganic hemostatic composition comprising zeolite with micropores and divalent metal cations, combined with trypsin in a specific mass ratio, which stabilizes the enzyme conformation and orientation on the surface, preventing inactivation and enhancing coagulation efficiency.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If inorganic hemostatic material (zeolite) is used to promote blood coagulation, then the coagulation process can be activated, but the coagulation time becomes too long (2-6 minutes) resulting in excessive hemorrhage and irreversible organ damage
Solution Approach 1:
The patent combines inorganic zeolite material with organic trypsin enzyme to create a composite hemostatic material. The zeolite provides structural support and activates coagulation factor XII, while the trypsin enzyme directly activates coagulation factor X, creating multiple activation pathways that significantly reduce coagulation time compared to using zeolite alone.
Solution Approach 2:
The patent divides the coagulation activation process into multiple parallel pathways: the intrinsic pathway activated by zeolite (through factor XII) and the direct activation pathway through trypsin (through factor X). This segmentation allows different parts of the coagulation cascade to be activated simultaneously, reducing overall coagulation time.
2Loss of time
If commercial biological hemostatic agents (thrombin, fibrin glue) are used to achieve rapid blood coagulation, then coagulation time is reduced (0.5-1 minute), but the manufacturing difficulty increases, purity requirements become higher, storage conditions become harsher, and cost increases significantly
Solution Approach 1:
The patent uses trypsin, a relatively inexpensive and stable enzyme compared to thrombin or fibrin glue, as the biological component. Trypsin can be produced through fermentation processes, making it more accessible and cost-effective while still achieving rapid hemostasis when combined with zeolite.
Solution Approach 2:
The patent changes the approach from using highly purified, temperature-sensitive proteins (thrombin, fibrin glue) to using a more stable enzyme (trypsin) that can be produced through fermentation. This parameter change in the biological agent's properties reduces manufacturing complexity and storage requirements while maintaining hemostatic effectiveness.
3Stability of the object's composition
If enzyme (trypsin) is combined with zeolite surface, then the enzyme conformation may be stabilized, but the rigid zeolite surface may cause enzyme inactivation and reduce reaction rate
Solution Approach 1:
The patent applies local quality by selectively modifying only the surface properties of the zeolite particles rather than the bulk material. The silane coating is applied only to the surface, creating a localized soft interface that stabilizes enzyme conformation without affecting the internal structure or catalytic activity of the zeolite.
Solution Approach 2:
The patent introduces silane coating as an intermediary layer between the rigid zeolite surface and the trypsin enzyme. This intermediary layer acts as a buffer that prevents direct contact between the enzyme and the rigid surface, reducing conformational changes and inactivation while allowing the enzyme to maintain its catalytic function.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition significantly shortens coagulation time, achieves effective hemostasis in emergency bleeding situations, and is cost-effective, offering a procoagulant activity comparable to or exceeding that of thrombin, making it suitable for patients with hemophilia.
Implementation Method 1
the zeolite contains divalent metal cations, and the mass ratio of the trypsin to the zeolite is 1:200-4:10... the zeolite stabilizes the enzyme conformation and orientation on the surface, preventing inactivation
Implementation Method 2
A bio-inorganic hemostatic composition comprising zeolite with micropores and divalent metal cations, combined with trypsin in a specific mass ratio... achieving effective hemostasis in emergency bleeding situations
Implementation Method 3
the coagulation function of thrombin is that thrombin directly cuts fibrinogen to form fibrin monomers, and finally forms cross-linked fibrin clot
Implementation Method 4
finally forms cross-linked fibrin clot under the action of coagulation factor XIIIa
Data Source
AI summary
Provided is a hemostatic composition comprising trypsin and zeolite, wherein pore channels of the zeolite are micropores, the zeolite contains divalent metal cations, and the mass ratio of the trypsin to the zeolite is 1:200-4:10. In the present invention, the trypsin specifically binds to the zeolite, allowing the trypsin to maintain a certain conformation on the surface of the zeolite and to obtain a higher procoagulant activity, thereby obtaining a hemostatic composition with an excellent blood coagulation effect. The hemostatic composition of the present invention has the advantages of a simple preparation method, low cost and convenient use, and can be widely used in hemostasis during trauma and operations, especially in emergent hemostasis in hemophilia patients.